Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a ...

Horton, a fourth-round pick by the Texans in 2023, played in 10 games as a rookie before stepping away from the team in late ...

When it was time to decide where he wanted to work, Dalton Cummins tells PEOPLE that going back to the hospital where he beat ...

Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology, today announced that it ...

A recent study derived from the adverse event reporting system of the Food and Drug Administration (FDA) showed that T-cell non-Hodgkin lymphomas were identified in 17 of 536 reports (3.2% ...

India continues to see a steady rise in the incidence of lymphoma, the most common type of blood cancer. But among all the ...

July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

September is Leukemia & Lymphoma Awareness Month. Oncologists diagnosed Skarzinski with stage 4 non-Hodgkin's B cell Lymphoma ...

Houston Texans defensive end Dylan Horton was activated from the reserve/non-football injured list Saturday, less than a year after he was diagnosed with late-stage Hodgkin lymphoma ...

Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim findings from three real-world studies in cutaneous ...